Jessica Lam1,2, Stephanie Baello3, Majid Iqbal2, Lauren E Kelly4, Patrick T Shannon5, David Chitayat6,7, Stephen G Matthews3, Gideon Koren1,2,4. 1. Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. 2. Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada. 3. Department of Physiology, Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada. 4. Department of Physiology and Pharmacology, University of Western Ontario, Toronto, Ontario, Canada. 5. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada. 6. Department of Obstetrics and Gynaecology, Prenatal Diagnosis and Medical Genetics Program, Mount Sinai Hospital, Toronto, Ontario, Canada. 7. Division of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Neonates have been shown to have a heightened sensitivity to the central depressive effects of opioids compared to older infants and adults. The limited development of P-glycoprotein (P-gp) may limit the ability of the neonate to efflux morphine from the brain back to the systemic circulation. The objective of the study was to determine the ontogeny of P-gp in the human brain. METHODS: Postmortem cortex samples from gestational age (GA) 20-26 wk, GA 36-40 wk, postnatal age (PNA) 0-3 mo, PNA 3-6 mo, and adults were immunostained for P-gp. RESULTS: The intensity of P-gp staining in adults was significantly higher compared to at GA 20-26 wk (P < 0.05), GA 36-40 wk (P < 0.05), and PNA 0-3 mo (P < 0.05). P-gp intensity at GA 20-26 wk (P < 0.05), GA 36-40 wk (P < 0.05), and PNA 0-3 mo (P < 0.05) was significantly lower compared to at PNA 3-6 mo. CONCLUSION: P-gp expression in the brain is limited at birth, increases with postnatal maturation, and reaches adult levels at ~3-6 mo of age. Given the immaturity of blood-brain barrier (BBB) P-gp after birth, morphine may concentrate in the brain. This provides mechanistic support to life threatening opioid toxicity seen with maternal codeine use during breastfeeding.
BACKGROUND: Neonates have been shown to have a heightened sensitivity to the central depressive effects of opioids compared to older infants and adults. The limited development of P-glycoprotein (P-gp) may limit the ability of the neonate to efflux morphine from the brain back to the systemic circulation. The objective of the study was to determine the ontogeny of P-gp in the human brain. METHODS: Postmortem cortex samples from gestational age (GA) 20-26 wk, GA 36-40 wk, postnatal age (PNA) 0-3 mo, PNA 3-6 mo, and adults were immunostained for P-gp. RESULTS: The intensity of P-gp staining in adults was significantly higher compared to at GA 20-26 wk (P < 0.05), GA 36-40 wk (P < 0.05), and PNA 0-3 mo (P < 0.05). P-gp intensity at GA 20-26 wk (P < 0.05), GA 36-40 wk (P < 0.05), and PNA 0-3 mo (P < 0.05) was significantly lower compared to at PNA 3-6 mo. CONCLUSION:P-gp expression in the brain is limited at birth, increases with postnatal maturation, and reaches adult levels at ~3-6 mo of age. Given the immaturity of blood-brain barrier (BBB) P-gp after birth, morphine may concentrate in the brain. This provides mechanistic support to life threatening opioid toxicity seen with maternal codeine use during breastfeeding.
Authors: Kerry B Goralski; Philip D Acott; Albert D Fraser; David Worth; Christopher J Sinal Journal: Drug Metab Dispos Date: 2005-11-22 Impact factor: 3.922
Authors: C Joakim Ek; Annamae Wong; Shane A Liddelow; Pia A Johansson; Katarzyna M Dziegielewska; Norman R Saunders Journal: Toxicol Lett Date: 2010-05-11 Impact factor: 4.372
Authors: Jason N Moore; Marc R Gastonguay; Chee M Ng; Susan C Adeniyi-Jones; David E Moody; Wenfang B Fang; Michelle E Ehrlich; Walter K Kraft Journal: Clin Pharmacol Ther Date: 2018-04-28 Impact factor: 6.875
Authors: C Rafaniello; M Sessa; F F Bernardi; M Pozzi; S Cheli; D Cattaneo; S Baldelli; M Molteni; R Bernardini; F Rossi; E Clementi; C Bravaccio; S Radice; A Capuano Journal: Pharmacogenomics J Date: 2017-07-18 Impact factor: 3.550
Authors: Kevin A Strauss; Charles E Ahlfors; Kyle Soltys; George V Mazareigos; Millie Young; Lauren E Bowser; Michael D Fox; James E Squires; Patrick McKiernan; Karlla W Brigatti; Erik G Puffenberger; Vincent J Carson; Hendrik J Vreman Journal: Hepatology Date: 2020-02-05 Impact factor: 17.425